Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation

被引:11
|
作者
Hai, Yang [1 ,2 ]
Zuo, Ling [1 ,3 ]
Wang, Meng [1 ,3 ]
Zhang, Ruoyu [1 ,3 ]
Wang, Munan [1 ,3 ]
Ren, Li [1 ,3 ]
Yang, Congwen [1 ,3 ]
Wang, Jianwei [1 ,3 ]
机构
[1] Tradit Chinese Med Key Lab Chongqing Prevent & Cur, Chongqing 400016, Peoples R China
[2] Chongqing Med Univ, Coll Basic Med, Chongqing 400016, Peoples R China
[3] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing 400016, Peoples R China
来源
MOLECULES | 2023年 / 28卷 / 02期
基金
中国国家自然科学基金;
关键词
fatty acid oxidation; icariin; liver lipid deposition; nonalcoholic fatty liver disease; polycystic ovary syndrome; DE-NOVO LIPOGENESIS; INFLAMMATION; CONTRIBUTES; METABOLISM; CYP4A; DIET;
D O I
10.3390/molecules28020517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
(1) Background: Icariin is the main component of the Chinese herb Epimedium. A number of studies have shown that it alleviates abnormal lipid metabolism. However, it is not clear whether and how icariin can ameliorate hepatic steatosis with polycystic ovary syndrome (PCOS). This study was designed to explore the anti-hepatosteatosis effect of icariin in rats with polycystic ovary syndrome. (2) Methods: Female Sprague Dawley(SD)rats were treated with a high-fat diet and letrozole for 21 days to make nonalcoholic fatty liver disease (NAFLD) in the polycystic ovary syndrome model. Then model rats were treated with icariin (by gavage, once daily) for 28 days. Serum hormones and biochemical variables were determined by ELISA or enzyme. RNA-sequence analysis was used to enrich related target pathways. Then, quantitative Real-time PCR (qRT-PCR) and Western blot were performed to verify target genes and proteins. (3) Results: Icariin treatment reduced excess serum levels of Testosterone (T), Estradiol (E2), Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), LH/FSH ratio, insulin, triglycerides (TG), and aspartate aminotransferase (AST) in high-fat diet (HFD) and letrozole fed rats. Meanwhile, icariin ameliorated HFD and letrozole-induced fatty liver, as evidenced by a reduction in excess triglyceride accumulation, vacuolization, and Oil Red O staining area in the liver of model rats. Results of RNA-sequencing, western blotting, and qRT-PCR analyses indicated that icariin up-regulated fatty acid translocase (CD36), in mitochondria, and peroxisome proliferator-activated receptor alpha (PPAR alpha) expression, which led to the enhancement of fatty acid oxidation molecules, such as cytochrome P450, family 4, subfamily a, polypeptide 3 (CYP4A3), carnitine palmitoyltransferase 1 alpha (CPT1 alpha), acyl-CoA oxidase 1 (ACOX1), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD). Besides, icariin reduced lipid synthesis, which elicited stearoyl-Coenzyme A desaturase 1 (SCD1), fatty acid synthase (FASN), and acetyl-CoA (ACC). (4) Conclusion: Icariin showed an ameliorative effect on hepatic steatosis induced by HFD and letrozole, which was associated with improved fatty acid oxidation and reduced lipid accumulation in the liver.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Nonalcoholic fatty liver disease and polycystic ovary syndrome
    Evangeline Vassilatou
    World Journal of Gastroenterology, 2014, (26) : 8351 - 8363
  • [2] Nonalcoholic fatty liver disease and polycystic ovary syndrome
    Vassilatou, Evangeline
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8351 - 8363
  • [3] Polycystic ovary syndrome and nonalcoholic fatty liver disease
    Macut, Djuro
    Bozic-Antic, Ivana
    Bjekic-Macut, Jelica
    Tziomalos, Konstantinos
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (03) : R145 - R158
  • [4] Nonalcoholic fatty liver disease and polycystic ovary syndrome
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    Kountouras, Jannis
    ANNALS OF HEPATOLOGY, 2015, 14 (06) : 941 - 943
  • [5] Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
    Paschou, Stavroula A.
    Polyzos, Stergios A.
    Anagnostis, Panagiotis
    Goulis, Dimitrios G.
    Kanaka-Gantenbein, Christina
    Lambrinoudaki, Irene
    Georgopoulos, Neoklis A.
    Vryonidou, Andromachi
    ENDOCRINE, 2020, 67 (01) : 1 - 8
  • [6] Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome
    Macut, Djuro
    Bjekic-Macut, Jelica
    Livadas, Sarantis
    Stanojlovic, Olivera
    Hrncic, Dragan
    Rasic-Markovic, Aleksandra
    Vojnovic Milutinovic, Danijela
    Mladenovic, Violeta
    Andric, Zoran
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) : 4593 - 4597
  • [7] Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
    Cerda, Cristian
    Perez-Ayuso, Rosa Maria
    Riquelme, Arnoldo
    Soza, Alejandro
    Villaseca, Paulina
    Sir-Petermann, Teresa
    Espinoza, Manuel
    Pizarro, Margarita
    Solis, Nancy
    Miquel, Juan Francisco
    Arrese, Marco
    JOURNAL OF HEPATOLOGY, 2007, 47 (03) : 412 - 417
  • [8] Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
    Stavroula A. Paschou
    Stergios A. Polyzos
    Panagiotis Anagnostis
    Dimitrios G. Goulis
    Christina Kanaka-Gantenbein
    Irene Lambrinoudaki
    Neoklis A. Georgopoulos
    Andromachi Vryonidou
    Endocrine, 2020, 67 : 1 - 8
  • [9] Nonalcoholic fatty liver disease risk in polycystic ovary syndrome patients
    Fernandez-Alonso, Ana M.
    Chedraui, Peter
    Perez-Lopez, Faustino R.
    GYNECOLOGICAL ENDOCRINOLOGY, 2024, 40 (01)
  • [10] Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome
    Falzarano, Claire
    Lofton, Taylor
    Osei-Ntansah, Adjoa
    Oliver, Trinitee
    Southward, Taylor
    Stewart, Salim
    Andrisse, Stanley
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (01): : 258 - 272